Levels of Blood Periostin Decrease after Acute Myocardial Infarction and are Negatively Associated with Ventricular Function after 3 Months

Cheng, Chi-Wen; Wang, Chao-Hung; Lee, Ju-Fang; Kuo, Li‐Tang; Cherng, Wen‐Jin

doi:10.2310/jim.0b013e3182408549

Cited by 21 publications

(23 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, the genotype of periostin was significantly correlated with plasma periostin level ( r 2 = −0.490, P < .039) and concluded that plasma periostin could be a promising biomarker for the estimation of early risk of CAD . However, in other study periostin levels were observed significantly lower in patients with acute myocardial infarction (AMI), after 1.3 ± 1.2 days as compared to the CAD and control group, respectively (175 ± 60, 245 ± 68, and 232 ± 63 ng/mL, P < .001) …”

Section: Resultsmentioning

confidence: 94%

“…33 However, in other study periostin levels were observed significantly lower in patients with acute myocardial infarction (AMI), after 1.3 ± 1.2 days as compared to the CAD and control group, respectively (175 ± 60, 245 ± 68, and 232 ± 63 ng/mL, P < .001). 34 Positive correlation was observed between Killip class (r = 0.395, .001). Similarly, the serum periostin level was found significantly higher in KD patients (42 549 ng/mL), when compared with febrile controls (P < .0086).…”

Section: Clinical Studiesmentioning

confidence: 92%

See 1 more Smart Citation

Periostin as a novel biomarker of cardiovascular disease: A systematic evidence landscape of preclinical and clinical studies

Azharuddin

Adil

Ghosh

et al. 2019

J Evidence Based Medicine

View full text Add to dashboard Cite

Background Periostin is a matricellular protein, expressed in various normal adult and fetal tissues. Recently, elevated periostin levels have been reported in heart failure, coronary artery disease, and stroke. However, there is lack of clinical studies to clarify the prognostic significance of systemic periostin levels in cardiovascular diseases (CVDs). The aim of the study was to perform a systematic review of published evidence on periostin and CVDs, and to clarify the diagnostic and prognostic significance of systemic periostin levels in CVDs. Methods A systematic search on PubMed was performed to identify relevant articles from inception to December 2018. The eligible studies evaluating the periostin expression and periostin levels in animal and human studies. Results A total of 24 relevant studies, including both animal and human data, were included. Periostin is significantly observed in myocardium tissue of failing hearts compared with control, and is also expressed in atherosclerotic plaques. Systemic periostin levels were significantly correlated with cardiac function and severity of CVD in several studies. A clinical study also observed positive correlation between periostin and N‐terminal pro b‐type natriuretic peptide (NT‐proBNP), highly sensitive troponin (hsTnT), and ST2 cardiac biomarker. Studies reported limited adjustment for potential confounders. Conclusions The evidence of current review support potential role of periostin in the pathophysiology of CVD. However, scarcity of data regarding the clinical use of periostin levels in the current management of CVDs further creates room for the future investigation. Therefore, further studies warrant to clarify its potential role, if any, as a novel cardiac biomarker.

show abstract

Section: Resultsmentioning

confidence: 94%

Section: Clinical Studiesmentioning

confidence: 92%

Periostin as a novel biomarker of cardiovascular disease: A systematic evidence landscape of preclinical and clinical studies

Azharuddin

Adil

Ghosh

et al. 2019

J Evidence Based Medicine

View full text Add to dashboard Cite

show abstract

“…16 Proteolysis induces secretion of extracellular domains, which together with a large group of noncanonical ligands may modulate Notch signaling. 24 Periostin (POSTN), a matricellular protein functioning as a noncanonical Notch ligand, 25 is regulated in clinical myocardial injury, 26 and is associated with cardiac dysfunction in end-stage HF. 22,23 To our knowledge, DLL1 is the only detectable canonical Notch ligand in human plasma/serum.…”

Section: Introductionmentioning

confidence: 99%

“…For noncanonical Notch ligands, delta-like 1 homologue (DLK1) is the most studied and has inhibitory effects on angiogenesis. 24 Periostin (POSTN), a matricellular protein functioning as a noncanonical Notch ligand, 25 is regulated in clinical myocardial injury, 26 and is associated with cardiac dysfunction in end-stage HF. 23 POSTN may modify Notch signaling through inhibition of DLK1 27 or maintenance of Notch1 receptor expression.…”

Section: Introductionmentioning

confidence: 99%

Circulating delta-like Notch ligand 1 is correlated with cardiac allograft vasculopathy and suppressed in heart transplant recipients on everolimus-based immunosuppression

Norum

Michelsen

Lekva

et al. 2019

American Journal of Transplantation

View full text Add to dashboard Cite

Cardiac allograft vasculopathy (CAV) causes heart failure after heart transplantation (HTx), but its pathogenesis is incompletely understood. Notch signaling, possibly modulated by everolimus (EVR), is essential for processes involved in CAV. We hypothesized that circulating Notch ligands would be dysregulated after HTx. We studied circulating delta‐like Notch ligand 1 (DLL1) and periostin (POSTN) and CAV in de novo HTx recipients (n = 70) randomized to standard or EVR‐based, calcineurin inhibitor‐free immunosuppression and in maintenance HTx recipients (n = 41). Compared to healthy controls, plasma DLL1 and POSTN were elevated in de novo (P < .01; P < .001) and maintenance HTx recipients (P < .001; P < .01). Use of EVR was associated with a treatment effect for DLL1. For de novo HTx recipients, a change in DLL1 correlated with a change in CAV at 1 (P = .021) and 3 years (P = .005). In vitro, activation of T cells increased DLL1 secretion, attenuated by EVR. In vitro data suggest that also endothelial cells and vascular smooth muscle cells (VSMCs) could contribute to circulating DLL1. Immunostaining of myocardial specimens showed colocalization of DLL1 with T cells, endothelial cells, and VSMCs. Our findings suggest a role of DLL1 in CAV progression, and that the beneficial effect of EVR on CAV could reflect a suppressive effect on DLL1. Trial registration numbers—SCHEDULE trial: ClinicalTrials.gov NCT01266148; NOCTET trial: ClinicalTrials.gov NCT00377962.

show abstract

“…Gene polymorphisms analysis in Chinese population showed that rs3829365 of the periostin gene was associated with susceptibility to, and severity of heart failure, suggesting a role of periostin in disease prediction and severity assessment [23]. Acute myocardial infarction patients showed decreased circulating level of periostin compared with control volunteers and periostin level was in negative correlation with patients’ cardiac function three months after AMI [24]. All these studies demonstrated that periostin acted as an important factor in the process of extracellular matrix remodeling under cardiac adverse conditions such as damage and pressure overload.…”

Section: Discussionmentioning

confidence: 99%

Association of Serum Periostin with Cardiac Function and Short-Term Prognosis in Acute Myocardial Infarction Patients

Lin

Cheng²,

Ding³

et al. 2014

PLoS ONE

View full text Add to dashboard Cite

BackgroundPeriostin was proved to play an important role in extra-cellular matrix remodeling after acute myocardial infarction (AMI). Myocardial periostin was markedly up-regulated after AMI and participated in the maladaptive process of cardiac remodeling. However, few researches focused on the circulating periostin and its significance. This study aims to investigate the association of serum periostin level with cardiac function and short-term prognosis in AMI patients.Methodology/Principal FindingsWe totally recruited 50 patients diagnosed as ST-elevation myocardial infarction. Blood samples were taken within 12 hours after the onset of AMI before emergency coronary revascularization procedures. Serum periostin was measured using enzyme-linked immunosorbent assay. All patients received echocardiography examination within one week after hospitalization. Correlations of serum periostin with echocardiography parameters, Killip class and myocardium injury biomarkers (CK-MB/troponin T) were investigated. AMI patients were divided into two groups by serum periostin level (higher/lower periostin group) and followed up for six months. Primary endpoints included cardiovascular mortality, nonfatal stroke/transient ischemic attack, chest pain occurrence and re-hospitalization. Secondary endpoint referred to composite cardiovascular events including all the primary endpoints.ResultSerum periostin was in negative association with left ventricular ejection fraction (LVEF) (r = −0.472, *p<0.01) and left atrium diameter (LAD) (r = −0.328, *p<0.05). Positive correlation was found between serum periostin level and Killip class (r = 0.395, *p<0.01). There was no association between serum periostin and CK-MB or troponin T (p>0.05). After six months follow up, patients in higher periostin group showed increased composite cardiovascular events (*p<0.05). Patients showed no significant difference in primary endpoints between the two groups.Conclusions/SignificanceSerum periostin was in negative correlation with LVEF and LAD, in positive association with Killip class and higher serum periostin level may be predictive for worse short-term disease prognosis indicated as more composite cardiovascular events six months post AMI.

show abstract

Levels of Blood Periostin Decrease after Acute Myocardial Infarction and are Negatively Associated with Ventricular Function after 3 Months

Abstract: Acute myocardial infarction is associated with a decrease in blood PN levels, and PN concentrations predict cardiac function 3 months after AMI.

Cited by 21 publications

References 26 publications

Periostin as a novel biomarker of cardiovascular disease: A systematic evidence landscape of preclinical and clinical studies

Periostin as a novel biomarker of cardiovascular disease: A systematic evidence landscape of preclinical and clinical studies

Circulating delta-like Notch ligand 1 is correlated with cardiac allograft vasculopathy and suppressed in heart transplant recipients on everolimus-based immunosuppression

Association of Serum Periostin with Cardiac Function and Short-Term Prognosis in Acute Myocardial Infarction Patients

Contact Info

Product

Resources

About